PharmNovo raised 67 MSEK in new funding!


PharmNovo is pleased to announce that we have raised 67 MSEK in a new share issue led by Sciety. Other significant investors include Karolinska Development, PolyPharmFlis AB, Almi Invest, and Almi Invest Syd. The new capital will be used to finance drug substance development, run the clinical phase I trial of the drug candidate PN6047, and continue the development of the company.

Per von Mentzer, CEO, comments:
“We are delighted to have secured this new capital and would like to thank everyone who has participated in the share issue for their great trust in PharmNovo. As a result, we are now well equipped to continue developing our treatment for neuropathic pain. We look forward to the first in-human-study, which is expected to start later this year.”

Göran Lerenius, Chairman of the board, comments:
“This successful capital raise is proof of the great interest in our work. In addition to the capital injection, it is also very satisfying to have a group of investors with us who share our vision of improving the quality of life for the millions of people who suffer from neuropathic pain.”

Read more:
Press release

Follow us:
PharmNovo – Cision News